Merck & (MRK) closed at $145.93 on Oct 16, 2026, up 0.5% on the day. The stock is down 0.8% over the past month, up 17.3% over three months, up 39.7% year to date and up 76.3% over the past year. It trades 7.0% below its 52-week high of $156.92 and 80.8% above its 52-week low of $80.72. The close sits above its 50-day moving average ($145.12) and above its 200-day moving average ($124.67).
NextPick tracks MRK in its Pharma basket alongside JNJ, ABBV, RHHBY, NVS and AZN. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month MRK ranks 8th of 12 basket members by price change.
MRK is scheduled to report earnings on Oct 29, 2026. Over its last 8 reports the stock moved an average of 2.4% on the first trading day after earnings, beating the options-implied move in 1 of 8.
MRK options were pricing 35% at-the-money implied volatility on Oct 7, 2026, an IV rank of 82 over the past year.
Merck & is scheduled to report on Oct 29, 2026.
Over the last 8 reports, MRK moved an average of 2.4% on the first trading day after earnings. The move beat the options-implied move in 1 of 8 reports.
Yes — the Oct 16, 2026 close of $145.93 is 17.1% above the 200-day average of $124.67.
MRK closed 7.0% below its 52-week high of $156.92.
NextPick groups MRK with JNJ, ABBV, RHHBY, NVS and AZN in its Pharma basket.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
